Publication | Open Access

Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically

Cancer ResearchHigh DoseMedicineImmunologyRecombinant Interleukin 2PathologyNeck PathologyHead And Neck CancerTemporary RegressionNeck OncologyImmunotherapyOncologyTreatment ResistanceTumor MicroenvironmentTumor Biology